Download The Medicines Transparency Alliance

The Medicines Transparency Alliance
Saul Walker
Senior Policy Advisor, Access to Medicines
Health Services Team
Pharmaceutical markets
• Public and private
• International and local interactions
• Information asymmetry
• Manufacturer/(regulator)/purchaser
• Wholesaler/Retailer
• Prescriber/(Dispenser)/Patient
• Lack of information
• Irrational – unaligned incentives
Page 2
The hypothesis …
Transparency
Validated Information &
Appropriate Disclosure
Mutual
Accountability
Multi-stakeholder
disclosure & scrutiny
Efficiency
(public/private)
Better policies,
improved business
practice & stronger
implementation
Page 3
Medicines Transparency Alliance
7 countries committed to work across government,
private sector and civil society to disclose data on
medicines price, quality, availability and promotion
Country Priorities
• Commit to disclosure and multi-
stakeholder approach
• Must include CSOs and private sector
• Decide where to locate secretariat and
stakeholder group
• Agree priority areas and work plan
• Guidance on disclosure from International
Secretariat
• Methodologies and technical support
Page 5
The Pilot
Pilot
New validated
data on
pharmaceutical
sector
Disclosure of
data and
scrutiny by
multistakeholder
group
Development of
policy options
Improved information for
management
££, toolkit &
technical
support
Policy change
and
implementation
Changes in drug
prices,
availability,
quality and/or
promotion
Improved processes.
Policy
research,
shared
learning
Sector plans,
domestic and
CPs
Page 6
Priorities chosen by countries
Activity area
Private sector mapping
national medicines / health framework
legislation
quality / regulation
evidence based selection & treatment
guidelines
procurement
distribution / supply chain
rational use of medicines
prices, affordability
medicines & insurance systems
promotion
operational research
website, disseminate findings
involving the media
PE GH ZM UG JO KG PH
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
v
Page 7
Data disclosure
(in addition to baseline)
• Pricing (Peru and Uganda)
• Availability and promotion (Jordan and
Zambia);
• Transparency and accountability
(Philippines - GGM)
• Quality (Kyrgyzstan and Ghana);
• Health insurance data mining (Ghana)
• RUM (Uganda and Jordan)
Page 8
Progress and Next Steps
• All countries have agreed work plans –
took longer than we expected
• Implementation now underway – focus
on newly disclosing & using information
• Baseline surveys underway
• Sector scan, availability, multi-stakeholder
working – significant new data resources
• Process evaluation 1Q10 – inform
decisions and design for post-pilot
Page 9
Questions
• Disclosure – what, when and to whom?
• Multi-stakeholder approach or multi-
stakeholder analysis?
• Catalysing support from others?
• Adding value or adding confusion?
Page 10
www.medicinestransparency.org
Page 11